

Naloxone: Understanding Its Community Use and Effectiveness

The increasing rates of fatal opioid overdoses over the last decade has emphasized the need for strategies that efficiently reduce mortality.¹ Approved by the United States Food and Drug Administration, naloxone (also referred to by the brand name, Narcan®) is an opioid overdose medication that reverses the effects of opioids in overdoses by replacing the opioids in a person's system, attaching to the receptors to which the opioids were bound.^{2,3,4} This document presents research-supported talking points on the effectiveness of naloxone and overdose education and naloxone distribution programs.

To find out how naloxone works in the body, watch this video: What Is Naloxone?

NALOXONE EFFECTIVENESS AND SAFETY

- Naloxone administration results in high rates of successful opioid overdose reversal. Opioid overdose events where naloxone is administered are reversed at rates between 83%-100%.^{5,6} Reductions due to naloxone distribution in community-level fatal overdoses mortality range from 37 to 90 percent.⁷
- Naloxone-related policies decrease the number of opioid-related deaths. Naloxone access and Good Samaritan laws are associated with a reduction of opioid-related fatalities ranging between 9 and 11 percent.^{8, 9}
- Naloxone administration is safe to use for overdose reversal. Serious adverse effects among overdose events where naloxone is administered are rare, with fewer than 1 percent reported.^{10,11}
- Communities with high saturation of naloxone distribution experience lower opioid overdose death rates. Take-home naloxone kits and Opioid Overdose Education and Naloxone Distribution (OEND) implementation lead to reduced opioidrelated deaths when compared to communities with lower rates of naloxone distribution.^{12,13,14}

NALOXONE TRAINING EFFECTIVENESS

• Almost anyone can successfully administer naloxone when adequately trained. Family members, law enforcement officers, traditional first responders, bystanders, and



those who use opioids (both prescription and nonprescription) can be trained to effectively reverse opioid-related overdoses by administering naloxone.^{12,15,16,17,18,19,20,21}

- **OEND training increases retained opioid-related knowledge and overdose reversal self-efficacy.** Training improves knowledge about responding to overdoses and increases the levels of self-reported confidence in one's perceived ability to administer naloxone and efficiently responding to an overdose event.^{15,17,18,22,23}
- Compared to untrained rescuers, trained rescuers are more likely to employ appropriate, recommended overdose reversal behaviors to victims of overdose. Laypersons, patients with opioid prescriptions, and their social network (e.g., families) who receive training in opioid overdose prevention education and naloxone administration are more likely to (1) stay with the overdose victim; (2) call 911 (or the appropriate emergency response team); (3) perform rescue breathing; and (4) use a naloxone kit.^{18,22,24,25}
- OEND trainings can be implemented through institutions such as hospitals as well as at the community level. Emergency departments and community-based organizations successfully provide training to potential rescuers, including bystanders and medical professionals.^{24,26} OEND-trained medical providers who counsel and prescribe naloxone to patients at risk of an opioid overdose, in turn, reduce fatalities.²³ Furthermore, training individuals at high risk for witnessing overdoses may reduce opioid overdose mortality at a population level.²⁷

COMMON MISPERCEPTIONS ABOUT NALOXONE

- Naloxone-related policies do not increase illicit use of prescription or nonprescription opioids. Variations of Naloxone access laws and Good Samaritan laws do not increase the recreational use of prescription painkillers.^{8,20}
- Patients prescribed naloxone are less likely than patients without a prescription of naloxone to have an overdose event. Patients who received a naloxone prescription experience up to 50 percent fewer opioid-related visits to the emergency department compared to patients without naloxone prescription within six months post-prescription.^{10,12}
- Law enforcement and first responders who administer naloxone may serve as referrers to non-fatal overdose victims to seek treatment.²⁸ First responders may serve as liaisons, connecting victims of overdose with the people, resources, services, and other support systems to prevent future overdose incidences and other adverse health outcomes.



- Naloxone has no abuse or dependence potential. Naloxone accelerates acute withdrawal symptoms in individuals with opiate-dependency and does not affect nonopioid related overdoses.^{5,29}
- When examining the cost per year of life gained to provide naloxone kits to laypeople including individuals who use opioids and likely overdose bystanders, **naloxone distribution is cost-effective**.^{7,30} Naloxone distribution may also be cost-saving when accounting for emergency medical service use and overdose-related cost.⁷

REFERENCES

- Centers for Disease Control and Prevention (CDC). (2017). Opioid Overdose. Available from <u>https://www.cdc.gov/drugoverdose/index.html</u>.
- National Institute on Drug Abuse (NIDA). (2017). Naloxone for Opioid Overdose: Life-Saving Science. Available from <u>https://www.drugabuse.gov/publications/naloxone-opioid-overdose-life-saving-science/naloxone-opioid-overdose-life-saving-science</u>
- National Institute on Drug Abuse (NIDA). (2018). Opioid Overdose Reversal with Naloxone (Narcan, Evzio). Available from <u>https://www.drugabuse.gov/related-topics/opioid-overdose-reversal-naloxone-narcan-evzio</u>
- 4. Substance Abuse and Mental Health Services Administration (SAMHSA). (2016). Naloxone. *Available from https://www.samhsa.gov/medication-assisted-treatment/treatment/naloxone*
- Seal, K. H., Thawley, R., Gee, L., Bamberger, J., Kral, A. H., Ciccarone, D., ... & Edlin, B. R. (2005). Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. *Journal of Urban Health*, 82(2), 303-311.
- Bird, S. M., Parmar, M. K., & Strang, J. (2015). Take-home naloxone to prevent fatalities from opiateoverdose: protocol for Scotland's public health policy evaluation, and a new measure to assess impact. *Drugs: Education, Prevention and Policy*, 22(1), 66-76.
- 7. Coffin, P. O., & Sullivan, S. D. (2013a). Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. *Annals of Internal Medicine*, *158*(1), 1-9.
- Rees, D. I., Sabia, J. J., Argys, L. M., Latshaw, J., & Dave, D. (2017). With a little help from my friends: The effects of naloxone access and good samaritan laws on opioid-related deaths (No. w23171). National Bureau of Economic Research.
- Bounthavong, M., Harvey, M. A., Wells, D. L., Popish, S. J., Himstreet, J., Oliva, E. M., ... & Christopher, M. L. (2017). Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis. *Journal of the American Pharmacists Association*, *57*(2), S68-S72.



- Coffin, P. O., Behar, E., Rowe, C., Santos, G. M., Coffa, D., Bald, M., & Vittinghoff, E. (2016). Nonrandomized intervention study of naloxone coprescription for primary care patients receiving longterm opioid therapy for pain. *Annals of internal medicine*, *165*(4), 245-252.
- Corrigan, M., Wilson, S. S., & Hampton, J. (2015). Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. *American Journal of Health-System Pharmacy*, 72(18), 1544-1554.
- 12. Kerensky, T., & Walley, A. Y. (2017). Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. *Addiction Science & Clinical Practice*, *12*(1), 4.
- McAuley, A., Aucott, L., & Matheson, C. (2015). Exploring the life-saving potential of naloxone: a systematic review and descriptive meta-analysis of take home naloxone (THN) programmes for opioid users. *International Journal of Drug Policy*, 26(12), 1183-1188.
- 14. Wheeler, E., Davidson, P. J., Jones, T. S., & Irwin, K. S. (2012). Community-based opioid overdose prevention programs providing naloxone—United States, 2010. *MMWR. Morbidity and mortality weekly report*, *61*(6), 101.
- Williams, A. V., Marsden, J., & Strang, J. (2014). Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. *Addiction*, *109*(2), 250-259.
- Clark, A. K., Wilder, C. M., & Winstanley, E. L. (2014). A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs. *Journal of Addiction Medicine*. 8(3), 153– 163.
- Espelt, A., Bosque-Prous, M., Folch, C., Sarasa-Renedo, A., Majó, X., Casabona, J., ... & REDAN Group. (2017). Is systematic training in opioid overdose prevention effective? *PloS one*, 12(10), e0186833.
- Mitchell, K., Durante, S. E., Pellatt, K., Richardson, C. G., Mathias, S., & Buxton, J. A. (2017). Naloxone and the Inner City Youth Experience (NICYE): a community-based participatory research study examining young people's perceptions of the BC take home naloxone program. *Harm Reduction Journal*, *14*(1), 34.
- 19. Behar, E., Santos, G. M., Wheeler, E., Rowe, C., & Coffin, P. O. (2015). Brief overdose education is sufficient for naloxone distribution to opioid users. *Drug & Alcohol Dependence*, *148*, 209-212.
- Doe-Simkins, M., Quinn, E., Xuan, Z., Sorensen-Alawad, A., Hackman, H., Ozonoff, A., & Walley, A. Y. (2014). Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. *BMC Public Health*, *14*(1), 297.



- Nolan, S., Buxton, J., Dobrer, S., Dong, H., Hayashi, K., Milloy, M. J., ... & Wood, E. (2017).
 Awareness, possession, and use of take-home naloxone among illicit drug users, Vancouver, British Columbia, 2014-2015. *Public Health Reports*, *132*(5), 563-569.
- 22. Tobin, K. E., Sherman, S. G., Beilenson, P., Welsh, C., & Latkin, C. A. (2009). Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. *International Journal of Drug Policy*, *20*(2), 131-136.
- Mueller, S. R., Walley, A. Y., Calcaterra, S. L., Glanz, J. M., & Binswanger, I. A. (2015). A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. *Substance Abuse*, *36*(2), 240-253.
- Dwyer, K., Walley, A. Y., Langlois, B. K., Mitchell, P. M., Nelson, K. P., Cromwell, J., & Bernstein, E. (2015). Opioid education and nasal naloxone rescue kits in the emergency department. *Western Journal of Emergency Medicine*, *16*(3), 381.
- 25. Giglio, R.E., Li, G., & DiMaggio, C.J. (2015). Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. *Injury Epidemiology*, *2*(1), 10.
- 26. Samuels, E. (2014). Emergency department naloxone distribution: A Rhode Island department of health, recovery community, and emergency department partnership to reduce opioid overdose deaths. *Rhode Island Medical Journal*, *97*(10), 38-39.
- Siegler, A., Huxley-Reicher, Z., Maldjian, L., Jordan, R., Oliver, C., Jakubowski, A., & Kunins, H. V. (2017). Naloxone use among overdose prevention trainees in New York City: A longitudinal cohort study. *Drug & Alcohol Dependence*, *179*, 124-130.
- Dahlem, C. H. G., King, L., Anderson, G., Marr, A., Waddell, J. E., & Scalera, M. (2017). Beyond rescue: Implementation and evaluation of revised naloxone training for law enforcement officers. *Public Health Nursing*, *34*(6), 516-521.
- 29. Jones, J.D., Campbell A., Metz V.E., & Comer S.D. (2017). No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. *Addictive Behaviors*, 71, 104-106.
- 30. Coffin, P. O., & Sullivan, S. D. (2013b). Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. *Journal of Medical Economics*, *16*(8), 1051-1060.